Drug Discovery Unit
We translate basic science into lead compounds to validate putative drug targets, to use as tools to investigate disease pathways and, when appropriate, advance to pre-clinical drug candidates.
We work to biotech style philosophy and standards incorporating, dynamic, goal driven project management based on target product profiles and compound selection criteria. Our major research themes are:
- neglected tropical diseases
- innovative targets and pathways
The DDU has all of the capabilities required for:
- early phase drug discovery
- assay development
- high throughput screening
- cell biology
- medicinal chemistry
- structural biology
- computational chemistry
All of these capabilities operate under one management structure to ensure an integrated approach and rapid progress.
Currently the team is about 120 people and includes substantial experience from the pharmaceutical/ biotech sector. This website contains details of current programmes and supporting infrastructure.
Senior leadership team
Extended leadership team
|Dr Beatriz Baragana||Apicomplexan Portfolio Manager||B.Baragana@dundee.ac.uk|
|Dr Laura Cleghorn||TB Portfolio Manager||L.A.T.Cleghorn@dundee.ac.uk|
|Dr Vincent Postis||Molecular Interaction Team Leaderfirstname.lastname@example.org|
|Dr Gary Tarver||Synthetic Methodologies Team Leaderemail@example.com|
A deadly disease that can kill victims who may never know they were infected is to be targeted by University of Dundee scientists following a multi-million funding award.
The University of Dundee is among the UK research organisations to benefit from a £118 million funding package to accelerate knowledge exchange, translation and commercialisation.
The life-changing work of one of Scotland’s foremost scientific institutions is to continue following a multi-million-pound award.